Dr. Pecora on Ovarian Cancer PARP Inhibitor

Andrew L. Pecora, MD, FACP, CPE
Published: Wednesday, May 18, 2011

Andrew L. Pecora, MD, FACP, CPE the Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center discusses new PARP inhibitor for ovarian cancer.

Dr. Pecora says in advanced ovarian cancer there have been few advances in therapeutic approaches, but he adds that will change. A class of agents called PARP inhibitors that block specific pathways in cancer cells. Data will show that patients receiving PARP inhibitors can have a prolongation of their progression free survival. Dr. Pecora says it doesn't appear to be limited to a specific subgroup and appears to be applicable to most ovarian cancer.
Andrew L. Pecora, MD, FACP, CPE the Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center discusses new PARP inhibitor for ovarian cancer.

Dr. Pecora says in advanced ovarian cancer there have been few advances in therapeutic approaches, but he adds that will change. A class of agents called PARP inhibitors that block specific pathways in cancer cells. Data will show that patients receiving PARP inhibitors can have a prolongation of their progression free survival. Dr. Pecora says it doesn't appear to be limited to a specific subgroup and appears to be applicable to most ovarian cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x